GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » Book Value per Share

Harpoon Therapeutics (Harpoon Therapeutics) Book Value per Share : $1.11 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Book Value per Share?

Harpoon Therapeutics's book value per share for the quarter that ended in Sep. 2023 was $1.11.

During the past 12 months, Harpoon Therapeutics's average Book Value Per Share Growth Rate was -78.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -65.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Harpoon Therapeutics was -65.80% per year. The lowest was -65.80% per year. And the median was -65.80% per year.

Harpoon Therapeutics's current price is $23.01. Its book value per share for the quarter that ended in Sep. 2023 was $1.11. Hence, today's PB Ratio of Harpoon Therapeutics is 20.82.

During the past 7 years, the highest P/B Ratio of Harpoon Therapeutics was 42.11. The lowest was 1.17. And the median was 4.00.


Harpoon Therapeutics Book Value per Share Historical Data

The historical data trend for Harpoon Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Book Value per Share Chart

Harpoon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Get a 7-Day Free Trial -22.37 37.83 21.07 17.72 1.51

Harpoon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.09 1.51 0.19 0.79 1.11

Competitive Comparison of Harpoon Therapeutics's Book Value per Share

For the Biotechnology subindustry, Harpoon Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harpoon Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's PB Ratio falls into.



Harpoon Therapeutics Book Value per Share Calculation

Harpoon Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(5.40-0.00)/3.58
=1.51

Harpoon Therapeutics's Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.54-0.00)/4.11
=1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Harpoon Therapeutics  (NAS:HARP) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Harpoon Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Executives
Vijay K Lathi 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker officer: Chief Medical Officer C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza officer: Principal Fin. & Acctng Ofc. C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail director 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt director, 10 percent owner C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170